Time filter

Source Type

PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: Genetics and molecular research : GMR | Year: 2012

The T-cell immunoglobulin and mucin domain 1 (TIM-1) is known to be associated with susceptibility to rheumatoid arthritis (RA). We investigated the association of four single-nucleotide polymorphisms (SNPs) in the promoter region of the TIM-1 gene with susceptibility to RA in a Chinese Hui ethnic minority group. Using RFLP or sequence specific primer-PCR, 118 RA patients and 118 non-arthritis control individuals were analyzed for the -1637A>G, -1454G>A, -416G>C, and -232A>G SNPs in the TIM-1 gene. The polymorphisms -232A>G and -1637A>G in the promoter region of TIM-1 were found to be associated with susceptibility to the RA gene in the Hui population, while -416G>C and -1454G>A SNPs were not. Of these, the polymorphism of -232A>G is inconsistent with that found in a Korean population, suggesting that genetic variations of the TIM-1 gene contribute to RA susceptibility in different ways among different populations. Based on haplotype analysis, individuals with haplotypes AGCA ((2) = 22.0, P < 0.01, OR (95%CI) >1), AGCG ((2) = 18.16, P < 0.01, OR (95%CI) >1) and AGGA ((2) = 5.58, P < 0.05, OR (95%CI) >1) are at risk to develop RA in the Chinese Hui population; those with the GAGA ((2) = 7.44, P < 0.01, OR (95%CI) <1) haplotype may have a decreased likelihood of RA. GGCA and GGCG are more common in both RA and non-RA subjects. We conclude that -1637A>G and -232A>G polymorphisms of TIM-1 are associated with susceptibility to RA in the Chinese Hui population.


PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: Biochemical genetics | Year: 2014

To investigate the association of eNOS gene polymorphism with essential hypertension in the Chinese Han population, we examined polymorphisms of the rs2070744 (TC), rs1800780 (AG), and rs3918181 (AG) loci. The results demonstrated that the genotypic frequency at the rs1800780 (AG) locus was significantly different between patients with essential hypertension and the control cohorts (P<0.05); while genotypic frequencies and allelic frequencies at rs2070744 (TC) and rs3918181 (AG) loci had no statistical difference between the patient group and controls (P>0.05). In addition, haplotype analysis found a statistically significant difference for haplotype TGA, with OR (95% CI) of 1.549 (1.116-2.150) (P<0.05). These findings suggest that polymorphism of rs1800780 (AG) in the eNOS gene may be one of the most important genetic factors associated with essential hypertension susceptibility, and those who have haplotype TGA may be at risk to develop essential hypertension.


PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: Current cancer drug targets | Year: 2013

Cancer is a disease caused by a series of genetic and epigenetic alterations. Therefore, agents targeting the genetic and/or epigenetic machinery offer potential for the development of anticancer drugs. Accumulating evidence has demonstrated that some common natural products [such as epigallocatechin-3-gallate (EGCG), curcumin, genistein, sulforaphane (SFN) and resveratrol] have anticancer properties through the mechanisms of altering epigenetic processes [including DNA methylation, histone modification, chromatin remodeling, microRNA (miRNA) regulation] and targeting cancer stem cells (CSCs). These bioactive compounds are able to revert epigenetic alterations in a variety of cancers in vitro and in vivo. They exert anticancer effects by targeting various signaling pathways related to the initiation, progression and metastasis of cancer. It appears that natural products hold great promise for cancer prevention and treatment by altering various epigenetic modifications. This review aims to discuss our current understanding of genetic and epigenetic targets of natural products and the effects of some common natural products on cancer chemoprevention and treatment.


PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: Genetics and molecular research : GMR | Year: 2013

We investigated a possible association of polymorphism of the eNOS gene and essential hypertension in the Chinese Hui population; polymorphisms of rs2070744 (T>C), rs1799983 (G>T), rs1800780 (A>G), and rs3918181 (A>G) loci of the eNOS gene were examined. We found that the genotypic frequencies at rs1799983 and rs1800780 loci differed significantly between patients with essential hypertension and control cohorts. The allelic frequency of the rs1799983 locus also differed significantly between essential hypertension patients and non-essential hypertension controls in this population. Additionally, the G allele of the rs1799983 locus was less frequent in the essential hypertension patients than in controls, with an odds ratio (OR) value of 3.851 [95% confidence interval (95%CI) = 2.236-6.631]. This is an indication of a protective factor of essential hypertension in Chinese Hui people. Haplotype analysis using the 4 SNPs revealed 15 haplotypes. Haplotype frequencies of CGAG, TTAG, TGGG, TTGG, and TTGA were significantly different in essential hypertension patients compared to non-essential hypertension controls. Individuals with haplotypes CGAG [ = 7.371, OR (95%CI) = 0.352 (0.161-0.770)] and TGGG [ = 6.180, OR (95%CI) = 0.600 (0.400- 0.899)] appear less likely to have essential hypertension. However, Chinese Hui with the haplotype TTAG are at risk to develop essential hypertension [ = 10.816, OR (95%CI) = 2.689 (1.466-4.932)]. We conclude that polymorphism of the eNOS gene is associated with susceptibility to essential hypertension in the Chinese Hui population.


PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: International journal of immunogenetics | Year: 2012

The T-cell immunoglobulin and mucin domains 1 (TIM-1) and 3 (TIM-3) have been shown to be associated with susceptibility to rheumatoid arthritis (RA) in many ethnicities. In this study, we investigated the rs7700944 polymorphism of the intron region of TIM-4 gene in Chinese Han and Hui populations, with and without RA in Ningxia Hui Autonomous Region of China. Our results demonstrated genetic variations of the TIM-4 gene, along with significantly different distributions of genotypes and alleles at rs7700944 site in these two populations, with or without RA (P < 0.01). In addition, a strong association between the polymorphism with RA susceptibility was found in the studies of Chinese Han and Hui ethnic groups (P < 0.01), although the risk genotype contributed to RA susceptibility was different between the Han and Hui groups (P < 0.01). The AG was the risk genotype for RA in Han population, while GG was the risk genotype at rs7700944 site of TIM-4 gene in Hui ethnicity. In addition to the genotype, the risk alleles of this single nucleotide polymorphism for RA in these two populations were also different, individuals with A allele was more susceptible to RA in Chinese Han [odds ratio (OR) = 1.930; 95% CI 1.412, 2.636; P < 0.01], but the risk allele in Hui was G in this study (OR = 1.823; 95% CI 1.330, 2.498; P < 0.01). These findings strongly suggest that polymorphism of rs7700944 of TIM-4 may be a potential genetic variant among distinguished populations, as well as an important genetic factor associated with the RA susceptibility in many ethnicities.


PubMed | Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China
Type: Journal Article | Journal: Expert opinion on biological therapy | Year: 2013

Lung cancer is the leading cause of cancer death worldwide. As clinical benefits to conventional cancer therapies are still formidable, there is an urgent need for novel agents and approaches to improve the overall clinical outcomes for patients with lung cancer.This article reviews the current understanding of targeted therapy for lung cancer with monoclonal antibodies (mAbs), mainly bevacizumab and cetuximab. The results from several key clinical trials validating the effectiveness and safety of bevacizumab and cetuximab, the relation of cancer biomarkers, the polymorphic correlation of targeted genes with the therapeutic outcome of mAb-based treatment, as well as the impact of Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial on personalised treatment of lung cancer are discussed.The addition of bevacizumab or cetuximab to chemotherapy has shown promising benefits to the patients with non-small-cell lung cancer. However, the overall benefits of mAb-based targeted therapy to lung cancer patients vary among individuals. It is therefore necessary to define reliable predictive biomarkers in an effort to better identify patients who are most likely to benefit from treatment with these novel agents in lung cancer.

Loading Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China collaborators
Loading Key Laboratory of the Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China collaborators